Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

VJHemOnc is pleased to be a Media Partner for the 2023 Tandem Meetings ❘ Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR, which are the combined annual meetings of the American Society for Transplantation and Cellular Therapy (ASTCT) and the Center for International Blood & Marrow Transplant Research (CIBMTR). These meetings featured the latest developments in the field of hematopoietic cell transplantation and cellular therapy.
View all videos

Tandem Meetings 2023

The Tandem Meetings I Transplantation & Cellular Therapy Meetings of ASTCT™ and CIBMTR®
15–19 February 2023 | Orlando, FL

Tandem Meetings 2023

The Tandem Meetings I Transplantation & Cellular Therapy Meetings of ASTCT™ and CIBMTR®
15–19 February 2023 | Orlando, FL
VJHemOnc is pleased to be a Media Partner for the 2023 Tandem Meetings ❘ Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR, which are the combined annual meetings of the American Society for Transplantation and Cellular Therapy (ASTCT) and the Center for International Blood & Marrow Transplant Research (CIBMTR). These meetings featured the latest developments in the field of hematopoietic cell transplantation and cellular therapy.
View all videos

Latest videos

View all videos
2:07
Outcomes with CD34-selected stem cell boost for poor graft function and graft failure after alloSCT
Muhammad Umair Mushtaq • 17 Feb 2023
3:32
Phase II study of panobinostat/GemBuMel with autoSCT in high-risk or R/R multiple myeloma
Yago Nieto • 13 Feb 2023
2:17
The impact of checkpoint inhibitor-based salvage regimens in patients with R/R HL undergoing autoSCT
Sanjal Desai • 21 Jan 2023
3:41
Preliminary results from Phase I study of CD123 CAR-T therapy in pediatric R/R AML
Swati Naik • 20 Feb 2023

Late-breaking abstracts

View all
5:08
LBA: CD33 CRISPR/Cas9 gene-edited donor allograft in patients with AML at risk of relapse post-HSCT
John DiPersio • 21 Feb 2023
2:55
LBA: update on Phase I study of rapcabtagene autoleucel in patients with R/R DLBCL
Nirav Niranjan Shah • 15 Feb 2023
3:45
LBA: outcomes of children and young adults with B-ALL following tisa-cel reinfusion
Kevin McNerney • 24 Feb 2023
4:04
LBA: Phase III study of Iomab-B prior to allogeneic transplantation vs conventional care in R/R AML
Rajneesh Nath • 20 Feb 2023

Transplantation

View all
5:14
Global trends in the use of stem cell transplantation for AML
Molly Tokaz • 2 Mar 2023
2:22
The benefit of autologous transplantation in the era of novel agents in multiple myeloma
Muzaffar Qazilbash • 24 Feb 2023

CAR-T therapy

View all
7:35
Survey on the evaluation and management of DLBCL following suboptimal response to CAR-T therapy
Nausheen Ahmed • 20 Feb 2023
3:12
Safety & efficacy of LV20.19 CAR-T therapy in Richter’s transformation and R/R MCL
Nirav Niranjan Shah • 15 Feb 2023

Leukemia

View all
4:13
ALL highlights: tisa-cel reinfusion in B-ALL & targeting CD5 and CD7 with CAR-Ts in T-ALL
John DiPersio • 21 Feb 2023
3:11
Predictive factors for HLH toxicity in patients with B-ALL treated with tisa-cel
Kevin McNerney • 24 Feb 2023

Lymphoma

View all
3:23
Real-world outcomes of patients with transformed R/R DLBCL treated with CD19 CAR-T therapy
Swetha Thiruvengadam • 23 Feb 2023
6:01
Update on ALLELE: tab-cel in patients with EBV+ PTLD following alloSCT after rituximab failure
Amer Beitinjaneh • 22 Feb 2023

Choose your cookie settings

VJHemOnc uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJHemOnc is intended for healthcare professionals